key: cord-0951387-nosh8awp
authors: Levine-Tiefenbrun, M.; Yelin, I.; Alapi, H.; Herzel, E.; Kuint, J.; Chodick, G.; Gazit, S.; Patalon, T.; Kishony, R.
title: Waning of SARS-CoV-2 booster viral-load reduction effectiveness
date: 2021-12-29
journal: nan
DOI: 10.1101/2021.12.27.21268424
sha: 1c803f357f792be51c4316f4aa96c09fc95c59ce
doc_id: 951387
cord_uid: nosh8awp

The BNT162b2 COVID-19 vaccine has been shown to reduce viral load of breakthrough infections (BTIs), an important factor affecting infectiousness. This viral-load protective effect has been waning with time post the second vaccine and later restored with a booster shot. It is currently unclear though for how long this regained effectiveness lasts. Analyzing Ct values of SARS-CoV-2 qRT-PCR tests of over 22,000 infections during a Delta-variant-dominant period in Israel, we found that this viral-load reduction effectiveness significantly declines within months post the booster dose. Adjusting for age, sex and calendric date, Ct values of RdRp gene initially increased by 2.7 [CI: 2.3-3.0] relative to unvaccinated in the first month post the booster dose, yet then decayed to a difference of 1.3 [CI: 0.7-1.9] in the second month and became small and insignificant in the third to fourth months. The rate and magnitude of this post-booster decline in viral-load reduction effectiveness mirror those observed post the second vaccine. These results suggest rapid waning of the booster's effectiveness in reducing infectiousness, possibly affecting community-level spread of the virus.

The Pfizer/BioNTech BNT162b2 vaccine 1,2 demonstrated high real-life effectiveness in prevention of infection and disease [3] [4] [5] as well as in reducing viral loads of breakthrough infections (BTIs) 6 . Indeed, national vaccination campaigns were initially followed by reduced infection rates, with the effect extending beyond the individual vaccinees to the community level [7] [8] [9] . Considering longer post-vaccination times, studies have shown that while vaccine effectiveness in preventing severe disease declines only mildly 10 , the effectiveness of protection against infection 2,11-13 and of reducing viral loads of BTIs strongly declines within several months 14 . A booster (third) dose was associated with restoring effectiveness of prevention of infection and disease 15 , as well as with reduction of BTI viral-loads 14 . Yet, it is unknown for how long these booster's regained effectiveness lasts and whether there will be a need for additional booster shots in the future 16 .

Here, we focus on the booster's association with reduced viral loads over time. We retrospectively collected and analyzed the reverse transcription quantitative polymerase chain reaction (RT-qPCR) test measurements of three SARS-CoV-2 genes -E, N and RdRp (Allplex 2019-nCoV assay, Seegene) -from positive tests of patients of Maccabi Healthcare Services (MHS). We focus on infections of adults over the age of 20 between June 28 and November 29 2021, before the Omicron variant started circulating in Israel, and when Delta was the dominant variant in the country (over 93%) 17 . Crossing this dataset with vaccination data, we identified in total 5,229 infections of unvaccinated, 16,038 BTIs of 2-dose-vaccinated and 1,390 BTIs of booster-vaccinated individuals (Methods: "Vaccination status", Extended Data Table 1 ).

For each of the three viral genes, we built a multivariable linear regression model for the relationship between Ct value and vaccination at different post-second-vaccination time bins and post-booster time bins, adjusted for sex, age and calendric date (Methods; n=22,657 infections). Consistent with our previous reports 6, 14 , regression coefficients for second-dose vaccinated, compared to unvaccinated, started with 4. Our study has a number of limitations. First, although viral load is a common proxy for infectiousness, a correlation between viral loads and infectability is not fully established. Second, differences in health-seeking behaviors may affect the timing at which individuals are tested and as viral load is associated with time post infection, such differences may in principle bias our results. Yet, we note that we minimized this effect by considering only the first positive test for each patient, which is typically performed within 5-6 days following infection, namely 1-2 days following symptoms 15, [18] [19] [20] .

In total, these initial observations show that the BNT162b2 booster regained effectiveness in reducing BTI viral loads is declining within months, in a rate and magnitude mirroring those observed post the second vaccine. Pending post-booster time-dependency data also on the effectiveness of disease prevention, these results warrant consideration of the long-term effectiveness of the mRNA vaccine and the possible benefit and anticipated duration of additional booster shots.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; KillCorona-Curbing Coronavirus Research Program (grant no. 3633/19 to R. K. and G.C.) and a fellowship from the Edmond J. Safra Center for Bioinformatics at Tel-Aviv University (to M. L-T). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 1,1,1,1,0,0,0], [1,1,1,1,1,1,0,0], [1,1,1,1,1,1,1,0], [1,1,1,1,1,1,1,1] for infections in unvaccinated, or 7-30 days, 31-60 days, 61-120 days, 121-180 days and over 180 days post the second vaccination, or 7-30 days, 31-60 days and 61-120 days post the booster.

Data availability. According to Israel Ministry of Health regulations, individual-level data cannot be shared openly. Specific requests for remote access to de-identified data should be referred to KSM, the Maccabi Healthcare Services Research and Innovation Center. Requests sent to Sarit Chehanowitz (chehanow_s@mac.org.il) will be considered within 21 d pending IRB approval and Maccabi Healthcare Services regulations.

Ethics committee approval. This study was approved by the MHS (Maccabi Healthcare Services) Institutional Review Board (IRB). Due to the retrospective design of the study,

Ct regression coefficients, indicating an infection Ct relative to unvaccinated control group (dashed line), show an initial increase in Ct in the first month after the second vaccination dose, which then gradually diminishes. Increased Ct is restored after the booster, yet this regained effectiveness also gradually diminishes. Coefficients were obtained by multivariate linear regression analysis, adjusting for age, sex and calendric date (Methods; n = 22,657). Error bars represent one standard error. All P values are two sided: 'ns', not significant, * P < 0.05, ** P < 0.01, *** P < 0.001. Data are shown for Ct of the RdRp gene; for genes N and E, see Extended Data Fig. 1a, b. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268424 doi: medRxiv preprint Extended Data Figure 3 . Regression coefficients for the association of Ct with two-dose vaccination and with the booster for non-hospitalized patients. Same model as in Fig. 1 and Extended Data Figure 1 , but excluding patients hospitalized due to COVID-19 (n = 22,271). Ct regression coefficients are shown for the RdRp (a), N (b) and E (c) genes. Error bars represent one standard error. All P values are two sided: 'ns', not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268424 doi: medRxiv preprint

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals

BNT162b2 mRNA vaccine effectiveness given confirmed exposure; Analysis 11

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Boosting immunity to COVID-19 vaccines. Nature medicine vol